Neuromelanin‐sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease
European Journal of Neuroscience · 2024
DOI: 10.1111/ejn.16296 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neuroscience, 2024. Verfasst von Yayun Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, China-Japan Union Hospital, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Melanins, Parkinson Disease, Magnetic Resonance Imaging, Biomarkers. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Science and Technology of Jilin Province.
Abstract (Originalsprache)
Parkinson's disease (PD) is an age‐related progressive neurodegenerative disorder characterized by both motor and non‐motor symptoms resulting from the death of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and noradrenergic neurons in the locus coeruleus (LC). The current diagnosis of PD primarily relies on motor symptoms, often leading to diagnoses in advanced stages, where a significant portion of SNpc dopamine neurons has already succumbed. Therefore, the identification of imaging biomarkers for early‐stage PD diagnosis and disease progression monitoring is imperative. Recent studies propose that neuromelanin‐sensitive magnetic resonance imaging (NM‐MRI) holds promise as an imaging biomarker. In this review, we summarize the latest findings concerning NM‐MRI characteristics at various stages in patients with PD and those with atypical parkinsonism. In conclusion, alterations in neuromelanin within the LC are associated with non‐motor symptoms and prove to be a reliable imaging biomarker in the prodromal phase of PD. Furthermore, NM‐MRI demonstrates efficacy in differentiating progressive supranuclear palsy (PSP) from PD and multiple system atrophy with predominant parkinsonism. The spatial patterns of changes in the SNpc can be indicative of PD progression and aid in distinguishing between PSP and synucleinopathies. We recommend that patients with PD and individuals at risk for PD undergo regular NM‐MRI examinations. This technology holds the potential for widespread use in PD diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, China-Japan Union Hospital, Jilin University, Changchun, China.
- Department of Radiology, China-Japan Union Hospital, Jilin University, Changchun, China.
ORCID-Profile: Ying Chang
Förderung
- Department of Science and Technology of Jilin Province
Zitieren
APA
Yan, Y., Zhang, M., Ren, W., Zheng, X., & Chang, Y. (2024). Neuromelanin‐sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease. European Journal of Neuroscience. https://doi.org/10.1111/ejn.16296
Vancouver
Yan Y, Zhang M, Ren W, Zheng X, Chang Y. Neuromelanin‐sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease. European Journal of Neuroscience. 2024. doi:10.1111/ejn.16296
BibTeX
@article{Yan2024,
author = {Yan, Yayun and Zhang, Mengchao and Ren, Wenhua and Zheng, Xiaoqi and Chang, Ying},
title = {Neuromelanin‐sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease},
journal = {European Journal of Neuroscience},
year = {2024},
doi = {10.1111/ejn.16296}
}
EUVIMED